DDInter1326 DDInter1376
Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resembles [clozapine] and only differs by two additional methyl groups and the absence of a chloride moiety. It was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Olanzapine {u} (Compound) resembles {v} (Compound) Clozapine
Olanzapine {u} (Compound) resembles {v} (Compound) Pirenzepine
Olanzapine {u} (Compound) binds {v} (Gene) HTR7
Olanzapine {u} (Compound) upregulates {v} (Gene) NNT
Olanzapine {u} (Compound) palliates {v} (Disease) Gilles de la Tourette syndrome
Olanzapine {u} (Compound) downregulates {v} (Gene) ITGAE
Olanzapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Olanzapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cetirizine
Olanzapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acarbose
Olanzapine {u} may lead to a major life threatening interaction when taken with {v} Potassium chloride
Olanzapine (Compound) resembles Clozapine (Compound)
Olanzapine (Compound) resembles Pirenzepine (Compound)
Olanzapine (Compound) binds HTR7 (Gene)
Olanzapine (Compound) upregulates NNT (Gene)
Olanzapine (Compound) palliates Gilles de la Tourette syndrome (Disease)
Olanzapine (Compound) downregulates ITGAE (Gene)
Olanzapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Acarbose
Olanzapine may lead to a major life threatening interaction when taken with Potassium chloride